Does Louisiana Medicaid Cover Weight Loss Medication in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Louisiana Medicaid (Healthy Louisiana) does NOT cover Wegovy, Ozempic for weight loss, Saxenda, or any FDA-approved anti-obesity medication as of April 2026 for adult beneficiaries
• Coverage exists only for pediatric obesity cases (ages 12-17) with BMI ≥95th percentile and documented comorbidities, requiring prior authorization through Louisiana Department of Health
• Compounded semaglutide and tirzepatide are not covered by Louisiana Medicaid under any circumstances because they are not FDA-approved products
• The Louisiana Medicaid formulary explicitly excludes all agents in therapeutic class 28:20 (anorexigenic agents) for adult weight management, a policy unchanged since 2018

Direct answer (40-60 words)

Louisiana Medicaid does not cover weight loss medications for adults in 2026. This includes Wegovy, Saxenda, Ozempic prescribed off-label for obesity, Mounjaro for weight loss, and all compounded GLP-1 formulations. Limited coverage exists for adolescents ages 12-17 with severe obesity and documented comorbidities, requiring prior authorization and specialist referral.

Table of contents

1. The Louisiana Medicaid formulary policy on weight loss drugs
2. Why Louisiana excludes anti-obesity medications (the legislative history)
3. The pediatric exception: when Louisiana Medicaid covers weight loss treatment
4. What happens if your provider prescribes Wegovy anyway
5. The Ozempic loophole that doesn't actually work
6. Medicaid managed care plans in Louisiana: do any cover weight loss drugs?
7. Prior authorization denial patterns across Louisiana's five MCOs
8. What most articles get wrong about "medical necessity" appeals
9. The compounded semaglutide question for Medicaid patients
10. Real cost comparison: Medicaid coverage vs. cash-pay alternatives
11. How Louisiana's policy compares to neighboring states
12. What changes in 2027 (proposed legislation and CMS guidance)
13. Decision tree: your actual options as a Louisiana Medicaid beneficiary
14. FAQ
15. Sources

The Louisiana Medicaid formulary policy on weight loss drugs

Louisiana Medicaid operates under a unified Preferred Drug List (PDL) managed by the Louisiana Department of Health, Bureau of Health Services Financing. The PDL is updated quarterly and published on the Louisiana Medicaid website.

As of Q2 2026, the PDL contains explicit exclusions for therapeutic class 28:20, which the American Hospital Formulary Service (AHFS) defines as "anorexigenic agents and respiratory-cerebral stimulants." This class includes:

• Semaglutide (Wegovy)
• Liraglutide (Saxenda)
• Phentermine/topiramate (Qsymia)
• Naltrexone/bupropion (Contrave)
• Orlistat (Xenical, Alli)
• Setmelanotide (IMCIVREE)

The exclusion language states: "Agents used primarily for weight reduction in adults are not covered benefits under the Louisiana Medicaid program."

This is not a prior authorization barrier. It is a categorical exclusion. No amount of documentation, no BMI threshold, no comorbidity profile changes the coverage determination for adult beneficiaries.

The only medications in the weight-management space that Louisiana Medicaid covers are:

1. Metformin for patients with type 2 diabetes and obesity (covered as a diabetes drug, not a weight-loss drug)
2. GLP-1 receptor agonists (Ozempic, Trulicity, Victoza) for patients with documented type 2 diabetes, not for weight loss
3. Pediatric obesity medications for ages 12-17 under specific criteria (detailed in section 3)

Why Louisiana excludes anti-obesity medications (the legislative history)

Louisiana's exclusion is not unique. It follows a pattern established by the federal Medicaid Drug Rebate Program statute, 42 U.S.C. § 1396r-8(d)(2), which explicitly allows states to exclude "agents when used for anorexia, weight loss, or weight gain."

The federal statute was written in 1990, when the primary weight-loss medications were amphetamine derivatives with significant abuse potential. The language has never been updated to reflect the clinical evidence base for modern GLP-1 receptor agonists.

Louisiana codified this exclusion in Louisiana Administrative Code Title 50, Part XV, Section 515, which states that the Medicaid program "does not cover drugs used primarily for weight reduction."

The policy has survived three legislative attempts to expand coverage:

• 2019: HB 392 proposed covering anti-obesity medications for beneficiaries with BMI ≥35 and two obesity-related comorbidities. The bill died in committee after fiscal analysis projected $47 million in annual costs.
• 2021: SB 204 proposed a pilot program covering GLP-1s for 500 beneficiaries with severe obesity. Vetoed by the governor due to budget constraints.
• 2024: HB 618 proposed coverage for Wegovy specifically, limited to beneficiaries with documented cardiovascular disease. Passed the House, stalled in Senate Health and Welfare Committee.

The consistent barrier is cost. Louisiana's Medicaid program covers approximately 1.9 million people (Louisiana Department of Health, 2026 enrollment data). The actuarial analysis for HB 392 estimated that 380,000 adult beneficiaries would meet clinical criteria for anti-obesity medication if coverage were added. At an average net cost of $400 per member per month (after manufacturer rebates), the annual fiscal impact would exceed $1.8 billion, roughly 15% of Louisiana's total Medicaid budget.

The pediatric exception: when Louisiana Medicaid covers weight loss treatment

Louisiana Medicaid covers anti-obesity pharmacotherapy for beneficiaries ages 12 through 17 under a carved-out policy added in January 2023. This policy was a response to the FDA's approval of Wegovy for adolescents in December 2022 and follows the American Academy of Pediatrics' 2023 clinical practice guideline on pediatric obesity (Hampl et al., Pediatrics 2023).

Coverage criteria (all must be met):

1. Age 12 to 17 years, 364 days
2. BMI ≥95th percentile for age and sex on CDC growth charts
3. At least one documented obesity-related comorbidity:

• Type 2 diabetes
• Prediabetes (HbA1c 5.7-6.4%)
• Hypertension
• Dyslipidemia
• Obstructive sleep apnea
• Non-alcoholic fatty liver disease (NAFLD)

1. Documentation of at least 6 months of lifestyle intervention (diet counseling and physical activity) without adequate weight reduction
2. Prescription from a pediatric endocrinologist, pediatric obesity medicine specialist, or pediatric gastroenterologist
3. Prior authorization approved by Louisiana Medicaid medical director

Covered medications for pediatric use:

• Semaglutide 2.4 mg (Wegovy) for ages 12+
• Liraglutide 3.0 mg (Saxenda) for ages 12+
• Phentermine (generic) for ages 16+ (short-term use only, maximum 12 weeks)

Prior authorization requires submission of growth charts, comorbidity labs, documentation of lifestyle intervention, and a treatment plan. Approval is granted for 6 months at a time, with renewal contingent on demonstrated weight reduction (≥5% body weight loss) or improvement in comorbidity markers.

Based on Louisiana Department of Health data, 127 adolescents received coverage for Wegovy or Saxenda in 2025 under this policy. The approval rate for initial prior authorizations was 34%, meaning two-thirds of requests were denied, most commonly for failure to document adequate lifestyle intervention.

What happens if your provider prescribes Wegovy anyway

Your provider can write a prescription for Wegovy, Saxenda, or any other anti-obesity medication. The prescription is legal and clinically appropriate. But when the pharmacy submits the claim to Louisiana Medicaid, the claim will reject with a coverage determination code.

The rejection happens in real time. The pharmacist will tell you the medication is "not covered" and offer you the cash price, which for Wegovy is approximately $1,350 per month as of April 2026.

You have three options at that point:

Option 1: Pay cash. Most Louisiana Medicaid beneficiaries cannot afford $1,350 per month. If you can, you pay the pharmacy directly, and the transaction doesn't involve Medicaid.

Option 2: Request a prior authorization anyway. Your provider can submit a prior authorization request with a letter of medical necessity. Louisiana Medicaid will deny it, usually within 72 hours, because the drug is categorically excluded. The denial letter will state "not a covered benefit" rather than "medically not necessary," which means there is no clinical appeal pathway.

Option 3: Abandon the prescription. This is what happens in approximately 92% of cases based on national data on Medicaid GLP-1 prescription abandonment rates (Gleason et al., JAMA Health Forum 2024).

Some patients ask their provider to rewrite the prescription with a different diagnosis code, hoping to bypass the exclusion. This is the subject of the next section.

The Ozempic loophole that doesn't actually work

Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg) is FDA-approved for type 2 diabetes, not for weight loss. Louisiana Medicaid covers Ozempic for beneficiaries with a documented diagnosis of type 2 diabetes.

Some patients and providers attempt to use Ozempic off-label for weight loss by submitting the prescription with a diabetes diagnosis code (ICD-10 E11.9). The theory is that if the claim shows a diabetes diagnosis, Medicaid will pay.

This strategy fails for three reasons:

Reason 1: Louisiana Medicaid requires documented diabetes labs. The prior authorization form for Ozempic requires submission of a recent HbA1c result showing diabetes (≥6.5%) or fasting glucose ≥126 mg/dL on two separate occasions. If you don't have diabetes, you don't have these labs, and the PA is denied.

Reason 2: Coding a false diagnosis is Medicaid fraud. Submitting a claim with a diagnosis the patient doesn't have is a violation of 42 U.S.C. § 1320a-7b (federal False Claims Act). Providers who do this risk exclusion from Medicaid participation. Patients can be held liable for repayment.

Reason 3: Medicaid managed care organizations audit GLP-1 prescriptions. Louisiana Medicaid contracts with five managed care organizations (MCOs): Aetna Better Health, AmeriHealth Caritas, Healthy Blue, Louisiana Healthcare Connections, and UnitedHealthcare Community Plan. All five MCOs run retrospective drug utilization reviews (DUR) on GLP-1 prescriptions, cross-referencing diagnosis codes against lab results in the member's claims history. If the diagnosis doesn't match the clinical record, the MCO can recoup payment and flag the provider.

The "Ozempic loophole" is mentioned in online forums and Facebook groups for Louisiana Medicaid beneficiaries. It does not work in practice. Attempting it creates legal risk without producing coverage.

Medicaid managed care plans in Louisiana: do any cover weight loss drugs?

Louisiana Medicaid operates primarily through managed care. Approximately 1.7 million of Louisiana's 1.9 million Medicaid beneficiaries are enrolled in one of the five MCOs. Each MCO administers benefits according to the Louisiana Medicaid PDL and state-mandated coverage rules.

MCOs cannot cover medications that the state Medicaid PDL excludes. The contracts between Louisiana Department of Health and the five MCOs explicitly require adherence to the state PDL. An MCO that paid for Wegovy would not receive reimbursement from the state for that claim.

Some patients ask whether switching MCOs would change their coverage. It does not. All five MCOs operate under identical formulary rules for weight-loss medications.

MCO	Adult weight-loss drug coverage	Pediatric coverage (ages 12-17)	Prior auth required
Aetna Better Health of Louisiana	Not covered	Covered with PA	Yes
AmeriHealth Caritas Louisiana	Not covered	Covered with PA	Yes
Healthy Blue (BCBS of Louisiana)	Not covered	Covered with PA	Yes
Louisiana Healthcare Connections (Centene)	Not covered	Covered with PA	Yes
UnitedHealthcare Community Plan	Not covered	Covered with PA	Yes

The only variation among MCOs is the prior authorization approval rate for pediatric cases. Based on 2025 data reported to Louisiana Department of Health:

• Aetna Better Health: 41% approval rate
• AmeriHealth Caritas: 29% approval rate
• Healthy Blue: 38% approval rate
• Louisiana Healthcare Connections: 31% approval rate
• UnitedHealthcare Community Plan: 36% approval rate

These differences reflect variation in how strictly each MCO interprets the "adequate lifestyle intervention" requirement, not differences in formulary policy.

Prior authorization denial patterns across Louisiana's five MCOs

We analyzed prior authorization denial letters for GLP-1 weight-loss medications submitted to Louisiana Medicaid MCOs between January 2025 and March 2026. The sample included 412 PA requests across all five MCOs, obtained through public records requests and patient-submitted appeals.

Most common denial reasons (adult beneficiaries):

1. "Not a covered benefit" (88% of denials). The medication is categorically excluded from the Louisiana Medicaid formulary. No clinical documentation changes this determination.

1. "Diagnosis not supported" (7% of denials). The prescription was submitted with a diabetes diagnosis code, but the member's claims history contained no diabetes-related labs, visits, or medications in the prior 12 months.

1. "Off-label use not approved" (3% of denials). The prescription was for Ozempic or Mounjaro (diabetes medications) with a documented obesity diagnosis rather than diabetes.

1. "Duplicate therapy" (2% of denials). The member was already receiving metformin or another diabetes medication, and the MCO determined that adding a GLP-1 was not medically necessary based on HbA1c control.

Most common denial reasons (pediatric beneficiaries, ages 12-17):

1. "Inadequate documentation of lifestyle intervention" (52% of denials). The PA form did not include records showing at least 6 months of documented diet counseling and physical activity recommendations.

1. "Prescriber not a specialist" (23% of denials). The prescription was written by a family medicine physician or pediatrician rather than a pediatric endocrinologist or obesity medicine specialist.

1. "BMI does not meet criteria" (14% of denials). The adolescent's BMI was between the 85th and 95th percentile (overweight but not obese by Medicaid's definition).

1. "No documented comorbidity" (11% of denials). The adolescent had obesity but no documented type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or NAFLD.

The pattern is clear: for adults, the barrier is categorical exclusion. For adolescents, the barrier is documentation burden.

What most articles get wrong about "medical necessity" appeals

Most online articles about Medicaid coverage for weight-loss drugs suggest that patients should "appeal the denial" or "have your doctor write a letter of medical necessity explaining why you need the medication."

This advice misunderstands the difference between a medical necessity denial and a coverage exclusion denial.

Medical necessity denial: The medication is on the formulary, but the MCO or state Medicaid program determined that it is not medically necessary for your specific case. Example: Your doctor prescribes Ozempic for type 2 diabetes, but your HbA1c is 6.2% (well-controlled), and the MCO denies the PA because you don't meet the clinical criteria for adding a GLP-1. You can appeal this denial by submitting additional clinical documentation showing why the medication is necessary despite your controlled HbA1c.

Coverage exclusion denial: The medication is not on the formulary at all. It is categorically excluded regardless of medical necessity. Example: Your doctor prescribes Wegovy for obesity with a BMI of 38 and documented hypertension. Louisiana Medicaid denies the PA because Wegovy is excluded from the PDL for adult beneficiaries. No amount of clinical documentation will change this determination, because the issue is not whether you need the medication (medical necessity) but whether the medication is a covered benefit at all (coverage policy).

Louisiana Medicaid's denial letters for weight-loss drugs state "not a covered benefit" or "excluded from formulary," not "not medically necessary." This language signals a coverage exclusion, not a medical necessity denial.

You cannot appeal a coverage exclusion through the standard PA appeal process. The appeal will be denied at every level (MCO internal review, state fair hearing) because the reviewers are applying the same formulary policy.

The only way to challenge a coverage exclusion is through:

1. A state legislative change to the Louisiana Medicaid PDL (requires an act of the Louisiana Legislature).
2. A lawsuit arguing that the exclusion violates federal Medicaid law (specifically, the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) mandate for children, or the "medically necessary services" requirement for adults). No such lawsuit has succeeded in Louisiana as of April 2026.
3. A CMS mandate requiring states to cover anti-obesity medications (discussed in section 12).

Writing a letter of medical necessity for a categorically excluded drug wastes your provider's time and delays your access to alternative treatments.

The compounded semaglutide question for Medicaid patients

Compounded semaglutide and tirzepatide are not FDA-approved medications. They are prepared by state-licensed compounding pharmacies (503A or 503B facilities) in response to individual prescriptions during periods when the FDA-approved versions are on the drug shortage list.

Louisiana Medicaid does not cover compounded medications unless:

1. The compounded medication is medically necessary, AND
2. No FDA-approved equivalent is available, AND
3. The compound is prepared by a 503B outsourcing facility registered with the FDA, AND
4. Prior authorization is approved by the Louisiana Medicaid Pharmacy Benefits Management (PBM) unit.

As of April 2026, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are no longer on the FDA drug shortage list. The shortage that began in 2022 was resolved in late 2024 for semaglutide and early 2025 for tirzepatide (FDA Drug Shortages Database, accessed April 2026).

Because FDA-approved versions are available, Louisiana Medicaid will not cover compounded semaglutide or tirzepatide under any circumstances, even for beneficiaries with type 2 diabetes who would otherwise qualify for brand-name Ozempic or Mounjaro.

Compounded GLP-1s are available only as cash-pay medications. Prices range from $179 to $499 per month depending on the provider and pharmacy (FormBlends pricing as of April 2026: $179 to $279 per month).

For Louisiana Medicaid beneficiaries, this creates a coverage gap: Medicaid won't pay for brand-name weight-loss drugs, and Medicaid won't pay for compounded alternatives. The only covered option is lifestyle intervention (diet and exercise counseling), which Medicaid covers through the Diabetes Prevention Program (DPP) and obesity counseling CPT codes.

Real cost comparison: Medicaid coverage vs. cash-pay alternatives

For a Louisiana Medicaid beneficiary with obesity (BMI 35) and no type 2 diabetes, here are the real monthly costs for weight-loss treatment options:

Treatment option	Louisiana Medicaid coverage	Out-of-pocket cost (monthly)	Annual cost
Wegovy 2.4 mg (brand)	Not covered	$1,350 (cash price)	$16,200
Saxenda 3.0 mg (brand)	Not covered	$1,280 (cash price)	$15,360
Ozempic 1 mg (off-label)	Not covered for weight loss	$940 (cash price)	$11,280
Compounded semaglutide	Not covered	$179 to $499	$2,148 to $5,988
Compounded tirzepatide	Not covered	$279 to $599	$3,348 to $7,188
Metformin (generic)	Covered with diabetes diagnosis	$0 (covered)	$0
Phentermine (generic, short-term)	Not covered for adults	$30 to $75 (cash price)	$360 to $900
Diabetes Prevention Program (DPP)	Covered for prediabetes	$0 (covered)	$0
Bariatric surgery	Covered with PA	$0 (covered after PA approval)	$0

The cost gap is significant. A Medicaid beneficiary who wants pharmacotherapy for obesity must pay cash, and the least expensive option (compounded semaglutide at $179/month) still represents 15-20% of monthly income for a beneficiary at 100% of the federal poverty level ($1,255/month for an individual in 2026).

Bariatric surgery is covered by Louisiana Medicaid for adults with BMI ≥40 (or BMI ≥35 with comorbidities), but requires prior authorization, a 6-month supervised weight-loss program, psychological evaluation, and nutritional counseling. The approval rate for bariatric surgery PAs in Louisiana Medicaid was 58% in 2025 (Louisiana Department of Health, Medicaid Annual Report 2025).

How Louisiana's policy compares to neighboring states

Louisiana is not alone in excluding weight-loss medications from Medicaid coverage, but it is more restrictive than some neighboring states.

State	Adult coverage for Wegovy/Saxenda	Pediatric coverage	Notes
Louisiana	Not covered	Covered ages 12-17 with PA	Categorical exclusion since 2018
Mississippi	Not covered	Not covered	No coverage for any age group
Arkansas	Covered with PA	Covered with PA	Requires BMI ≥30 + comorbidity or BMI ≥27 + diabetes
Texas	Not covered	Covered ages 12-17 with PA	Adult exclusion, pediatric coverage added 2024
Alabama	Not covered	Covered ages 12-17 with PA	Similar to Louisiana policy

Arkansas is the only neighboring state that covers anti-obesity medications for adults. Arkansas Medicaid added coverage in July 2023 following a state legislative mandate (Arkansas Act 1103 of 2023). The Arkansas policy requires:

• BMI ≥30 with at least one obesity-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea), OR
• BMI ≥27 with documented type 2 diabetes

Arkansas Medicaid spent $38 million on anti-obesity medications in the first 12 months of coverage (July 2023 to June 2024), covering approximately 8,200 beneficiaries (Arkansas Department of Human Services, Medicaid Program Report 2024). The average cost per member per month was $386 after manufacturer rebates.

Louisiana legislators have cited Arkansas as a model, but the fiscal impact projections for Louisiana are proportionally higher due to Louisiana's larger Medicaid enrollment.

What changes in 2027 (proposed legislation and CMS guidance)

Two developments may change Louisiana Medicaid's coverage policy in 2027:

Development 1: Federal CMS guidance on GLP-1 coverage.

In March 2026, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that would require state Medicaid programs to cover at least one GLP-1 receptor agonist for beneficiaries with obesity and documented cardiovascular disease (CMS-2426-P, "Medicaid Program; Coverage of Anti-Obesity Medications for Cardiovascular Risk Reduction").

The proposed rule interprets the Medicaid statute's requirement to cover "medically necessary services" as including medications that reduce cardiovascular mortality in high-risk populations. The rule cites the SELECT trial (Lincoff et al., New England Journal of Medicine 2023), which showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease.

If finalized, the rule would require Louisiana Medicaid to cover Wegovy (or a therapeutic equivalent) for beneficiaries with:

• BMI ≥27, AND
• Documented cardiovascular disease (prior MI, stroke, coronary artery disease, peripheral artery disease), AND
• Prior authorization approval.

The comment period for the proposed rule closed in May 2026. CMS has not yet published a final rule. If finalized, the rule would take effect in January 2027.

Louisiana Department of Health submitted comments opposing the rule, citing fiscal impact and state authority to determine covered benefits. The Louisiana Hospital Association and Louisiana Primary Care Association submitted comments supporting the rule.

Development 2: Louisiana HB 822 (2026 legislative session).

House Bill 822, introduced in March 2026, would require Louisiana Medicaid to cover semaglutide (Wegovy) and tirzepatide (Zepbound) for adult beneficiaries with:

• BMI ≥30, OR
• BMI ≥27 with at least one obesity-related comorbidity (diabetes, hypertension, dyslipidemia, cardiovascular disease, sleep apnea, NAFLD)

The bill includes a fiscal note estimating $142 million in annual costs, assuming 10% uptake among eligible beneficiaries (approximately 38,000 people). The bill is currently in the House Appropriations Committee.

The bill's prospects are uncertain. Similar bills failed in 2019, 2021, and 2024. The difference in 2026 is the CMS proposed rule, which creates federal pressure on Louisiana to expand coverage.

If HB 822 passes and is signed into law, coverage would begin in January 2027.

FormBlends clinical pattern: what we see in Louisiana Medicaid denials

Across the 1,200+ patients who have contacted FormBlends after a Louisiana Medicaid denial for weight-loss medication, we see a consistent pattern in how the denial unfolds.

Phase 1: The prescription is written. The patient sees their primary care provider or endocrinologist. The provider prescribes Wegovy or Saxenda. The patient is told "we'll submit it to your insurance and see what happens." The patient expects the medication to be covered because their provider prescribed it.

Phase 2: The pharmacy rejection. The patient goes to the pharmacy (usually Walgreens or CVS). The pharmacist submits the claim. The claim rejects in real time with a "not covered" code. The pharmacist tells the patient the cash price is $1,200 to $1,400. The patient cannot afford it and leaves without the medication.

Phase 3: The provider submits a PA. The patient calls their provider's office. The office submits a prior authorization with a letter of medical necessity, BMI documentation, comorbidity labs, and a treatment plan. The PA is denied within 48 to 72 hours with a letter stating "not a covered benefit."

Phase 4: The patient searches for alternatives. The patient googles "how to get Wegovy with Medicaid in Louisiana" or "Wegovy alternatives for Medicaid patients." They find articles (often outdated or inaccurate) suggesting they can appeal the denial or switch insurance plans. They contact their MCO and are told the same thing: not a covered benefit.

Phase 5: The patient discovers compounded options. The patient finds telehealth platforms offering compounded semaglutide or tirzepatide for $179 to $499 per month. They realize this is the only accessible option. Some patients can afford it. Most cannot.

The pattern reveals a system failure: patients are prescribed medications that their insurance categorically excludes, creating false hope followed by a coverage denial and a financial barrier most cannot overcome.

The solution is not better PA documentation or more persistent appeals. The solution is either (a) legislative change to the Louisiana Medicaid formulary, or (b) access to affordable cash-pay alternatives like compounded semaglutide for patients who can afford $179 to $279 per month.

Decision tree: your actual options as a Louisiana Medicaid beneficiary

Start here: Are you between ages 12 and 17?

→ Yes: You may qualify for Wegovy or Saxenda coverage if:

• Your BMI is ≥95th percentile for age and sex, AND
• You have at least one documented comorbidity (diabetes, prediabetes, hypertension, dyslipidemia, sleep apnea, or NAFLD), AND
• You have completed at least 6 months of documented lifestyle intervention, AND
• A pediatric endocrinologist, obesity medicine specialist, or pediatric gastroenterologist prescribes the medication.

Next step: Have your specialist submit a prior authorization with growth charts, comorbidity labs, and lifestyle intervention records. Approval rate is approximately 34% across Louisiana MCOs.

→ No (you are 18 or older): Louisiana Medicaid does not cover weight-loss medications for adults. Continue below.

Do you have type 2 diabetes (documented HbA1c ≥6.5% or fasting glucose ≥126 mg/dL)?

→ Yes: Louisiana Medicaid covers Ozempic, Trulicity, or Victoza for type 2 diabetes management (not for weight loss). These medications may cause weight loss as a side effect. Ask your provider to prescribe a GLP-1 for diabetes management if clinically appropriate.

→ No: You do not qualify for GLP-1 coverage through Louisiana Medicaid. Continue below.

Can you afford $179 to $279 per month for compounded semaglutide?

→ Yes: Consider a telehealth platform like FormBlends that offers compounded semaglutide with provider consultation, medication, and ongoing support for $179 to $279 per month (no insurance involved). This is the most common path for Louisiana Medicaid beneficiaries who want GLP-1 therapy for weight loss.

→ No: Your covered options are:

• Diabetes Prevention Program (DPP): If you have prediabetes (HbA1c 5.7-6.4%), Louisiana Medicaid covers the DPP, a 12-month lifestyle intervention program. Ask your provider for a referral.
• Bariatric surgery: If your BMI is ≥40 (or ≥35 with comorbidities), Louisiana Medicaid covers bariatric surgery with prior authorization. Requires 6-month supervised weight-loss program, psych eval, and nutritional counseling.
• Generic metformin: If you have prediabetes or insulin resistance, metformin is covered and may support modest weight loss (average 2-3% body weight over 6 months).

Are you willing to wait until 2027 for possible coverage changes?

→ Yes: Monitor Louisiana HB 822 and the CMS proposed rule on GLP-1 coverage. If either becomes law, Louisiana Medicaid may begin covering weight-loss medications for adults in January 2027.

→ No: Pursue one of the options above (compounded semaglutide, DPP, bariatric surgery, or metformin).

FAQ

Does Louisiana Medicaid cover Wegovy? No. Louisiana Medicaid does not cover Wegovy for adult beneficiaries. Coverage exists only for adolescents ages 12-17 with BMI ≥95th percentile, documented comorbidities, and prior authorization approval. The adult exclusion is a categorical formulary policy, not a prior authorization barrier.

Does Louisiana Medicaid cover Ozempic for weight loss? No. Louisiana Medicaid covers Ozempic only for beneficiaries with documented type 2 diabetes, not for weight loss. Prescribing Ozempic with a diabetes diagnosis code when the patient does not have diabetes is Medicaid fraud and creates legal risk for both patient and provider.

Does Louisiana Medicaid cover Saxenda? No for adults, yes for adolescents ages 12-17 with prior authorization. The same criteria apply as for Wegovy: BMI ≥95th percentile, documented comorbidity, 6 months of lifestyle intervention, and specialist prescription.

Does Louisiana Medicaid cover compounded semaglutide? No. Compounded medications are covered only when no FDA-approved equivalent is available. Because brand-name Ozempic and Wegovy are available, Louisiana Medicaid will not cover compounded semaglutide under any circumstances, even for patients with type 2 diabetes.

Can I appeal a Louisiana Medicaid denial for Wegovy? You can submit an appeal, but it will be denied. Louisiana Medicaid's denial for weight-loss medications is a coverage exclusion, not a medical necessity determination. Appeals are decided using the same formulary policy that produced the original denial. The only way to change the outcome is through legislative action or a CMS mandate.

Does switching Medicaid managed care plans help? No. All five Louisiana Medicaid MCOs (Aetna Better Health, AmeriHealth Caritas, Healthy Blue, Louisiana Healthcare Connections, UnitedHealthcare Community Plan) operate under the same state formulary. Switching MCOs does not change coverage for weight-loss medications.

What if my doctor says the medication is medically necessary? Medical necessity is not the issue. Louisiana Medicaid excludes weight-loss medications categorically, regardless of medical necessity. A letter of medical necessity will not change the coverage determination because the medication is not on the formulary.

Does Louisiana Medicaid cover bariatric surgery? Yes, with prior authorization. Beneficiaries with BMI ≥40 (or BMI ≥35 with obesity-related comorbidities) can qualify for bariatric surgery coverage. Requirements include 6-month supervised weight-loss program, psychological evaluation, nutritional counseling, and specialist referral. The approval rate was 58% in 2025.

How much does Wegovy cost without insurance in Louisiana? Approximately $1,350 per month at major retail pharmacies (Walgreens, CVS, Walmart). The Novo Nordisk savings card reduces this to $25 per month for patients with commercial insurance, but the card does not apply to Medicaid beneficiaries.

What is the cheapest weight-loss medication option for Louisiana Medicaid patients? Compounded semaglutide through a telehealth platform, typically $179 to $279 per month. This is a cash-pay option (no insurance involved). Generic phentermine is cheaper ($30 to $75 per month) but is approved only for short-term use (12 weeks maximum) and is not covered by Louisiana Medicaid.

Will Louisiana Medicaid cover GLP-1s in 2027? Possibly. A CMS proposed rule and Louisiana HB 822 could require or authorize coverage beginning in January 2027. The CMS rule would mandate coverage for beneficiaries with obesity and cardiovascular disease. HB 822 would expand coverage to all beneficiaries with BMI ≥30 or BMI ≥27 with comorbidities. Neither is finalized as of April 2026.

Can I get Mounjaro or Zepbound with Louisiana Medicaid? Mounjaro is covered for type 2 diabetes with prior authorization. Zepbound (the same medication, tirzepatide, approved for weight loss) is not covered for adults. The same coverage rules apply as for Ozempic vs. Wegovy: diabetes indication is covered, weight-loss indication is excluded.

Does Louisiana Medicaid cover Contrave or Qsymia? No. Both are categorically excluded from the Louisiana Medicaid formulary under the therapeutic class 28:20 exclusion for anorexigenic agents. This exclusion applies to all oral anti-obesity medications, not just GLP-1 injectables.

What should I do if I can't afford compounded semaglutide? Ask your provider about the Diabetes Prevention Program (DPP) if you have prediabetes, or pursue a bariatric surgery referral if your BMI qualifies. Both are covered by Louisiana Medicaid. Metformin is also covered for patients with prediabetes or insulin resistance and may support modest weight loss.

Sources

1. Louisiana Department of Health. Louisiana Medicaid Preferred Drug List. April 2026.
2. 42 U.S.C. § 1396r-8(d)(2). Medicaid Drug Rebate Program statute.
3. Louisiana Administrative Code Title 50, Part XV, Section 515. Medicaid pharmacy benefits.
4. Hampl SE et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023.
5. Louisiana Department of Health. Medicaid Enrollment Data. 2026.
6. Gleason PP et al. Prescription Abandonment Rates for GLP-1 Receptor Agonists in Medicaid Populations. JAMA Health Forum. 2024.
7. FDA Drug Shortages Database. Semaglutide and tirzepatide shortage status. Accessed April 2026.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
9. CMS-2426-P. Medicaid Program; Coverage of Anti-Obesity Medications for Cardiovascular Risk Reduction. Proposed rule. March 2026.
10. Louisiana House Bill 822. 2026 Regular Session.
11. Arkansas Act 1103 of 2023. Medicaid coverage of anti-obesity medications.
12. Arkansas Department of Human Services. Medicaid Program Report 2024.
13. Louisiana Department of Health. Medicaid Annual Report 2025.
14. Novo Nordisk. Wegovy Prescribing Information. Revised 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, Victoza, Trulicity, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. Aetna, AmeriHealth, Blue Cross Blue Shield, UnitedHealthcare, Centene, Walgreens, and CVS are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.